Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St futures subdued as Nvidia results, inflation take center stage
- Oil drops to more than two-week low on Iran-Oman talks to reopen Strait of Hormuz
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Arcturus Therapeutics (ARCT) Tops Q3 EPS by $1.01
November 14, 2023 4:02 PM ESTArcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
... More